Methods of use for CAR T cells
The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
1. A nucleic acid encoding a chimeric antigen receptor (CAR) comprising:
(a) a polynucleotide encoding an anti-fluorescein scFv and nucleic acid having at least about 95% sequence identity to SEQ ID NO:01, or 04; or
(b) a polynucleotide having the sequence set forth in SEQ ID NO:01, or 04.
2. A polypeptide encoded by the nucleic acid of claim 1 .
3. The polypeptide of claim 2 , wherein said polypeptide comprises or consists of humanized, or human amino acid sequences.
4. A cell comprising the polypeptide of claim 3 .
5. A cell comprising the polypeptide of claim 2 .
6. The cell of claim 5 , wherein the cell is a T lymphocyte or cytotoxic T lymphocyte.
7. A method of ameliorating or treating a folate receptor-expressing cancer in a patient comprising:
labeling the cancer in said patient with a small molecule comprising a folate linked to a fluorescein isothiocyanate (FITC) moiety; and
administering to said patient the cell of claim 5 .
8. The method of claim 7 , wherein the cell is administered before labeling the cancer with the small molecule.
9. The method of claim 7 , wherein the cell is an autologous cell.
10. A vector comprising the nucleic acid of claim 1 .
11. A cell comprising the vector of claim 10 .
12. The vector of claim 10 , wherein said vector is a lentiviral vector.
13. A cell comprising the vector of claim 12 .
14. A method of ameliorating or treating a folate receptor-expressing cancer in a patient comprising:
labeling the cancer in said patient with a small molecule comprising a folate linked to a fluorescein isothiocyanate (FITC) moiety; and
administering to said patient a composition comprising the vector of claim 12 .
15. A cell comprising the nucleic acid of claim 1 .
16. The cell of claim 15 , wherein the cell is a T lymphocyte or cytotoxic T lymphocyte.
17. A method of ameliorating or treating a folate receptor-expressing cancer in a patient comprising:
labeling the cancer in said patient with a small molecule comprising a folate linked to a fluorescein isothiocyanate (FITC) moiety; and
administering to said patient the cell of claim 15 .
18. The method of claim 17 , wherein the cell is a T lymphocyte or cytotoxic T lymphocyte.
19. The method of claim 18 , wherein the cell is an autologous cell.
20. The method of claim 17 , wherein the cell is administered before labeling the cancer with the small molecule.
21. The method of claim 17 , wherein the cell is an autologous cell.
22. The nucleic acid of claim 1 comprising a polynucleotide having at least 95% sequence identity to SEQ ID NO:01.
23. The nucleic acid of claim 1 comprising a polynucleotide having at least 95% sequence identity to SEQ ID NO:04.